Vutrisiran?

What is vutrisiran?

Vutrisiran is a medicine used for transthyretin amyloidosis (ATTR). It works by reducing levels of transthyretin protein produced by the liver, which helps lower the buildup of amyloid deposits associated with ATTR disease.[1]

What condition is it used to treat in ATTR amyloidosis?

Vutrisiran is indicated for ATTR amyloidosis, including forms where transthyretin builds up and causes organ damage over time.[1]

How is vutrisiran given (and how often)?

Vutrisiran is administered by injection.[1]

Who makes vutrisiran?

The drug is marketed under the brand name Amvuttra.[1]

What should patients ask their clinician?

Patients typically ask about which subtype of ATTR they have, how vutrisiran compares with other treatments, dosing schedule, monitoring needs, and what side effects to watch for.[1]

Sources

[1] https://www.drugs.com/amvuttra.html